PF-Atlas › Mechanisms › GLP-1 receptor agonists (semaglutide/liraglutide) show anti-fibrotic + anti-inflammatory effects across organs
GLP-1 receptor agonists (semaglutide/liraglutide) show anti-fibrotic + anti-inflammatory effects across organs in IPF
Mechanism of action · idiopathic pulmonary fibrosis
Overview
GLP-1 receptor agonists (semaglutide/liraglutide) show anti-fibrotic + anti-inflammatory effects across organs is a therapeutic target in idiopathic pulmonary fibrosis. PF-Atlas tracks 1 drug and 0 clinical trials acting through this mechanism.
Drugs targeting GLP-1 receptor agonists (semaglutide/liraglutide) show anti-fibrotic + anti-inflammatory effects across organs
Therapies
Medical disclaimer. This is a research summary, not medical advice.